• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases

Article

Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.

“Over the 20 years I’ve been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress,” said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.

Dr Seidman says that at the Annual Meeting of the American Society of Clinical Oncologists in Chicago, Aki Morikawa, MD, PhD, Memorial Sloan-Kettering Cancer Center, will present data on two commonly used breast cancer drugs, capecitabine and Lapatinib, to penetrate into breast cancer brain metastases. The observations found in the study should motivate further studies to examine the use of these agents.

This video was taken on May 31, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.